Biogen (BSP:BIIB34) Construction In Progress

: R$0 Mil (As of Mar. 2023)

View and export this data going back to 2016. Start your Free Trial

Biogen's quarterly construction in progress increased from Sep. 2022 (R$0 Mil) to Dec. 2022 (R$4,662 Mil) but then declined from Dec. 2022 (R$4,662 Mil) to Mar. 2023 (R$0 Mil).

Biogen's annual construction in progress declined from Dec. 2020 (R$10,036 Mil) to Dec. 2021 (R$4,356 Mil) but then increased from Dec. 2021 (R$4,356 Mil) to Dec. 2022 (R$4,662 Mil).

Biogen Construction In Progress Historical Data

The historical data trend for Biogen's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Construction In Progress

6,828.96

8,555.42

10,036.28

4,355.97

4,662.11

Biogen Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Construction In Progress																-	-	-	4,662.11	-

Biogen Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

Biogen (BSP:BIIB34) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (BSP:BIIB34) » Definitions » Construction In Progress

Comparable Companies

Traded in Other Exchanges

BIIB:USA BIIB:Mexico IDP:Germany BIIB:Austria BIIB:Argentina

Address

225 Binney Street, Cambridge, MA, USA, 02142

Website

http://www.biogen.com

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021, followed by Leqembi in January 2023.

Biogen (BSP:BIIB34) Headlines

No Headlines